Khan Abdul Rehman, Awan Fazli Rabbi
National Institute for Biotechnology and Genetic Engineering, Faisalabad, Pakistan.
Pak J Pharm Sci. 2012 Oct;25(4):889-901.
Diabetes mellitus in general and Type 2 Diabetes (T2D) in particular, are very complex diseases with heterogeneous etiology. T2D results from the impaired secretion or action of the insulin with a clinical phenotype of persistent hyperglycemia in the uncontrolled subjects. The disease clinical features appear after several years of latent preclinical asymptomatic conditions. Thus, when the disease is full blown, there are limited chances to reverse the disease phenotype; however, it can be managed by controlling diet, changing life style and using medicines. Understanding pathological mechanisms whereby genetic and/or environmental factors contribute to the development of diabetes is important for the prevention and treatment of the disease. In this regard, approaches such as genomics, transcriptomics, proteomics and metabolomics are being applied to identify more specific biomarkers for T2D for its early detection, management and devising new therapies. The emphasis of the present review is to provide updates on the applications of proteomics in addressing T2D with a focus on protein based biomarker discovery. Moreover, the idea of personalized medicine and intervention is also discussed for diabetes treatment in proteomics perspective.
一般而言,糖尿病,尤其是2型糖尿病(T2D),是病因异质性很强的复杂疾病。T2D是由胰岛素分泌受损或作用受损引起的,在未得到控制的患者中具有持续高血糖的临床表型。该疾病的临床特征在数年的潜伏临床前无症状期后出现。因此,当疾病全面爆发时,逆转疾病表型的机会有限;然而,可以通过控制饮食、改变生活方式和使用药物来进行管理。了解遗传和/或环境因素导致糖尿病发生的病理机制对于该疾病的预防和治疗很重要。在这方面,基因组学、转录组学、蛋白质组学和代谢组学等方法正在被应用于识别更特异的T2D生物标志物,用于其早期检测、管理以及设计新疗法。本综述的重点是提供蛋白质组学在解决T2D方面应用的最新情况,重点是基于蛋白质的生物标志物发现。此外,还从蛋白质组学角度讨论了糖尿病治疗中的个性化医疗和干预理念。